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Cerebral small vessel disease (SVD) and inflammation are increasingly recognized as key contributors to
Alzheimer's disease (AD), although the timing, trajectory, and relation between them early in the disease
process is unclear. Therefore, to investigate very early-stage changes, we compared 158 healthy midlife
adults with and without inherited AD predisposition (APOE4 carriership (38% positive), parental family
history (FH) of dementia (54% positive)) on markers of SVD (white matter hyperintensities (WMH),
cerebral microbleeds), and inflammation (C-reactive protein (CRP), fibrinogen), cross-sectionally and
longitudinally over two years. While WMH severity was comparable between groups at baseline, lon-
gitudinal progression of WMH was greater in at-risk groups (APOE4þ and FHþ). Topographically, APOE4
was associated exclusively with deep, but not periventricular, WMH progression after adjusting for FH.
Conversely, APOE4 carriers displayed lower CRP levels than noncarriers, but not fibrinogen. Furthermore,
interaction analysis showed that FH moderated the effect of SVD and inflammation on reaction time, an
early feature of SVD, but not episodic memory or executive function. Findings suggest that vascular and
inflammatory changes could occur decades before dementia onset, and may be of relevance in predicting
incipient clinical progression.
 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Alzheimer's disease (AD) is a neurodegenerative disorder
traditionally characterized by aberrant protein accumulation in the
brain. In recent years, however, our understanding of AD etiology
has expanded, implicating cerebral small vessel disease (SVD) and
inflammation as key players in its pathogenesis (Bos et al., 2018;
Heneka et al., 2015; Kinney et al., 2018; Wardlaw et al., 2013).
However, the timing and contribution of these alterations early in
the disease process remain unclear. This is an important gap to fill,
as developing our understanding of vascular and inflammatory
changes in the preclinical phase sheds light on the early trajectory
and mechanistic pathways leading up to dementia, and thus facil-
itates early detection and disease management.
In AD, subclinical biological changes are detectable many years
before observable symptom onset (Ritchie et al., 2016). Given theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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before disease onset would occur and thereby examine early alter-
ations in asymptomatic individuals at higher risk of developing AD.
Using this approach, we investigate longitudinal changes in SVD and
inflammation in relation with established heritable risk factors,
apolipoprotein ε4 (APOE4) (Strittmatter and Roses, 1996), and
parental family history (FH) of dementia (Scarabino et al., 2016).
Radiological findings of SVD are common in the elderly popu-
lation, and their presence predicts future dementia and risk of
stroke (Debette et al., 2019). However, associations between
inherited risk of dementia and SVD have been predominantly
examined in cross-sectional studies, reporting largely discrepant
findings depending on age cohorts. For instance, 2 studies of older
adults, with mean ages of 64 and 74 years, respectively, reported
significant associations between heritable risk factors and SVD
(Stamm et al., 2019; Wolters et al., 2017). Yet, a study of younger
adultsdaged 52 years old on averageddid not find evidence of
such an association (Stefaniak et al., 2018). These contrasting re-
ports suggest that the effect of inherited risk on vascular alterations
may emerge only in older age and suggests a need to consider the
longitudinal progression of neurovascular injury.
Inflammation is increasingly implicated in neurodegenerative
diseases such as AD (Gabin et al., 2018; Gong et al., 2016; Heneka
et al., 2015; Kinney et al., 2018; Tao et al., 2018). Under normal
circumstances, inflammation is a protective biological response to
infections and injuries. However, prolongation of an inflammatory
response can have deleterious effects on surrounding tissue.
Although the immune system is independent of the central nervous
system, the two are engaged in constant bidirectional communi-
cation. In pathologic states, the central nervous system can be
affected by systemic inflammation. Chronic systemic inflammation
can compromise the integrity of the bloodebrain barrier, thereby
allowing the entry of toxins and pathogens into the brain, and
activating glial cells (Bendorius et al., 2018; Kempuraj et al., 2017).
Blood markers of inflammation have been linked to neurodegen-
erative conditions including AD (Gabin et al., 2018; Gong et al.,
2016; Tao et al., 2018), cognitive decline (Noble et al., 2010;
Watanabe et al., 2016), and SVD (Low et al., 2019). However, there
has been a lack of research considering longitudinal changes in
systemic inflammation in relation to heritable AD risk.
To address the existing gaps in literature, the core objective of
our study was to investigate the influence of inherited dementia
risk on the longitudinal progression of SVD and inflammation in
cognitively healthy midlife adults. There is also significant merit in
elucidating the pathologic contributions to early cognitive decline,
as evidenced by recent findings that even subtle cognitive declineFig. 1. Participant selein preclinical AD has robust clinical utility in predicting disease
progression and conversion (Papp et al., 2020). Therefore, we
further examined the interaction between these pathologic
markers and inherited risk factors on neuropsychological measures.
In addition, we tested the association between SVD and inflam-
mation and whether these relationships would be moderated by
inherited risk. We hypothesized that SVD and inflammation would
differ by APOE4 carriership and FH in terms of progression, but not
cross-sectionally, and that these pathologies would be more
detrimental to clinical measures in individuals with inherited pre-
disposition to dementia, relative to those without.
2. Material and methods
2.1. Participants
The protocol of the PREVENT-Dementia study has been
described in detail previously (Ritchie and Ritchie, 2012). Cogni-
tively healthy, midlife (age 40e59 years) participants were
recruited through multiple sources. Majority of participants with
parental family history of dementia (FHþ) were recruited from the
dementia register database held at West London Mental Health
National Health Service Trust, which holds information on patients
with dementia and cognitive impairment who have consented to be
approached for clinical research, and their careers (often offspring),
or through memory clinic referralsdmost FHþ participants there-
fore had parents with a confirmed diagnosis of dementia. On the
other hand, majority of FH participants were spouses/friends/
other relatives of FHþ participants. Other participants were
recruited via the Join Dementia Research website (https://www.
joindementiaresearch.nihr.ac.uk/) or by registering their interest
through the PREVENT-Dementiawebsite (https://preventdementia.
co.uk/) and public presentations and engagement sessions.
This study included 158 participants who underwent clinical
assessment and magnetic resonance imaging (MRI) at both baseline
and two-year follow-up (mean ¼ 2.03 years; range ¼
1.91e2.48 years) (Fig. 1). The research was approved by the London-
Camberwell St Giles National Health Service Ethics Committee, and
all subjects provided written informed consent. Family history of
dementia was defined as positive (FHþ) if participants reported at
least one parent having clinically diagnosed dementia, while APOE4
status was regarded positive for 1 ε4 allele (APOE4þ). Sixty were
APOE4 carriers (38.0%), whereas 85 had a FH of dementia (53.8%),
more often on thematernal (35.4%) rather than paternal side (13.3%),
while 5.0% had both mothers and fathers with dementia. In terms of
parental dementia subtype, majority of FHþ subjects reportedction flowchart.
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13 reported vascular dementia (15%), and 8 were unsure or reported
other dementia subtypes (9%). Four participants carrying both the
APOE2 and APOE4 allelewere analyzed as APOE4 carriers. Given that
FH and APOE4may have independent contributions to dementia risk
(Donix et al., 2012), the two were analyzed as separate risk factors.
2.2. Imaging analysis
All participants underwent structuralMRI at baseline and two-year
follow-up. MRI scans were acquired on a 3T Siemens Verio. Three-
dimensional T1-weighted MPRAGE parameters were: 160 slices,
repetition time (TR)¼ 2300ms, echo time (TE)¼ 2.98ms, flip angle¼
9, voxel size ¼ 1  1  1mm3. Fluid-attenuated inversion recovery
(FLAIR) parameters were: 27 slices, TR ¼ 9000 ms, TE ¼ 94 ms, flip
angle ¼ 150, voxel size ¼ 0.43  0.43  4mm3. Susceptibility-
weighted imaging (SWI) parameters were: 72 slices, TR ¼ 28 ms,
TE ¼ 20 ms, flip angle ¼ 15, voxel size ¼ 0.72  0.72  1.2 mm3.
2.3. Quantification of white matter hyperintensities
White matter hyperintensities (WMH) lesion maps were ob-
tained using an automated script on the Statistical Parametric
Mapping 8 (SPM8) suite (http://www.fil.ion.ucl.ac.uk/spm/) on
FLAIR MRI; details on the procedures involved have been described
previously (Firbank et al., 2003). Briefly, SPM8 was used to perform
segmentation of T1-weighted images into gray matter (GM), white
matter, and cerebrospinal fluid, based on prior probability maps.
Using the GM andWMmaps, a brain mask was created and used toFig. 2. Radiological markers of cerebral small vessel disease (SVD). (A) White matter hyper
follow-up; (B) Classification of periventricular and deep WMH based on threshold distanc
bleeds were identified on 3T SWI scans, and progression was defined as the occurrence ofperform removal of nonbrain matter from the FLAIR images. WMH
segmentation was then conducted in FLAIR native space. Initial
WMH maps were obtained using threshold-based segmentation at
a threshold of 1.2 times the median pixel intensity, i.e., lesions with
pixel intensity more than 1.2 times the median intensity of the
whole brain were included in the WMH map. All lesion maps from
both baseline and follow-up visits were reviewed by a single-
experienced rater (A.L.) blinded to all clinical information,
including FH, APOE4 status, and blood inflammatory levels (Fig. 2).
Lesion maps obtained from the segmentation procedure were used
as starting points for manual WMH delineation. Baseline and
follow-up FLAIR images were evaluated side by side during delin-
eation to ensure consistency. WMH volumes were normalized by
total intracranial volume to account for individual differences in
head size ((WMH/total intracranial volume) * 100%) and trans-
formed using cube root transformation due to skewness.
WMHwere classified into periventricular and deep WMH based
on threshold distance from ventricles. Binary masks of ventricles
underwent 4 iterations of morphological dilation inMNI space. This
dilated ventricle mask was then transformed to subject space to
define the boundary between periventricular and deep WMH.
Because of the transformation, this is a variable distance accounting
for individual brain size and is approximately 10 mm, in line with
recommendations (Griffanti et al., 2018).2.4. Cerebral microbleed assessment
Cerebral microbleeds (CMB) were identified on 3T SWI
following the Microbleed Anatomical Rating Scale (MARS) whichintensities (WMH) were manually delineated on FLAIR MRI at baseline and two-year
e from ventricles, derived from morphological ventricle dilation; (C) Cerebral micro-
new microbleeds at follow-up, which were confirmed to be absent at baseline.
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keeping with the MARS, lobar regions were defined according to
Stark and Bradley (Stark and Bradley Jr, 1999), comprising cortical
and subcortical regions, while deep regions included the basal
ganglia, thalamus, internal capsule, external capsule, corpus cal-
losum, and deep and periventricular WM (anatomical diagram
available in Gregoire et al., 2009). Following the recommendations
made by Greenberg et al. (2009), CMB were defined as areas of
round/ovoid black signals, excluding tubular or linear structures
(Greenberg et al., 2009) (Fig. 2). Suspected microbleeds were cross-
validated on T1- and T2-weighted scans to exclude microbleed
“mimics”. In instances of uncertainty, microbleeds were labeled as
“possible microbleeds”dthis includes situations whereby micro-
bleeds cannot be distinguished fromvascular flow voids. Such cases
of “possible microbleeds” were excluded from analysis, and only
“definite microbleeds” were analyzed. All CMB identified at follow-
up were cross-checked against baseline scans to confirm their
presence at baseline, and new CMB were flagged. Microbleed pro-
gression was defined as the presence of any new CMB at follow-up
that were confirmed to be absent at baseline and was analyzed as a
binary variable (new CMB vs. no new CMB). Ratings were per-
formed blinded to all clinical information including FH, APOE4
carriership, and blood analysis.
2.5. Neuropsychological measures
Participants underwent neuropsychological assessment at base-
line and two-year follow-up. As part of the COGNITO battery (Ritchie
et al., 2014), participants were assessed on reaction time, episodic
memory, and executive function. Reaction time was measured using
a simple reaction time task administered through a touchscreen
which records responses and response latencies, and mean reaction
time across 12 trials was computed. Episodic memory was assessed
using a delayed free recall task of 9 names, and executive function
was evaluated using the Stroop test item of COGNITO.
2.6. Genotyping
TaqMan genotyping on QuantStudio12 K Flex was used to
establish APOE variants. Genomic DNA was isolated from whole
blood and genotyping was performed in 384 well plates, using the
TaqMan polymerase chain reaction (PCR)-based method. The final
volume PCR was 5 mL using 20 ng of genomic DNA, 2.5 mL of TaqMan
Master Mix, and 0.125 mL of 40 Assay by Design Genotyping Assay
Mix, or 0.25 mL of 20 Assay on Demand Genotyping Assay. The
cycling parameters were 95 for 10 minutes, followed by 40 cycles
of denaturation at 92 for 15 seconds and annealing/extension at
60 for one minute. PCR plates were then read on Thermo Fisher
QuantStudio 12K Flex Real-Time System instrument with Quant-
Studio 12K Flex Software or TaqMan Genotyper Software v1.3.
2.7. Inflammatory markers
Systemic inflammation was quantified using serum measures of
CRP and fibrinogen. Participants provided fasting blood samples on
themorning of their first visit, the same day as clinical and cognitive
assessments. Technicians were blinded to all clinical information.
CRP concentration in serum was assessed using the Beckman
Coulter AU System with a CRP Latex reagent. Following the latest
recommendations of best practices, participants with CRP
exceeding 10mg/L (n¼ 6) were excluded fromCRP analysis as these
may be attributable to an acute immune response (Mac Giollabhui
et al., 2020). Fibrinogen was measured using the Clauss method
(Clauss, 1957) by determining the clotting time of diluted plasmaafter the addition of thrombin. CRP and fibrinogen data underwent
cube root transformation due to right-tailed skewness.
2.8. Statistical analysis
Standard statistical techniques were used for descriptive ana-
lyses (Table 1). To test whether FH and APOE4 carriership differed in
baseline levels of SVD (WMH and CMB) and inflammation (CRP and
fibrinogen), we independently fitted regression models to each of
these outcomes of interest (simple linear regression models fitted
to WMH, CRP, and fibrinogen; logistic regression models fitted to
binary CMB variable). In all models, we adjusted for sex (1 ¼ male,
2 ¼ female), age (centered at sample mean of 52.2 years), and years
of education (centered at sample mean of 16.1 years) (corre-
sponding results in Section 3.1). To assess whether FH and APOE4
carriership were associated with the trajectory of WMH, CRP, and
fibrinogen, independent linear mixed effects models were fitted to
each outcome of interest, allowing intercepts to vary between
subjects and adjusted for the same covariates, while CMB pro-
gression was analyzed as a dichotomized variable (no new CMB vs.
1 new CMB) using logistic regression analysis (corresponding
results in Section 3.2).
To test associations between SVD (WMH and CMB) and
inflammation (CRP and fibrinogen) at baseline, regression models
were fitted to WMH and CMB in separate models, and to examine
whether these associations were moderated by group (FH, APOE4
carriership), we repeated the analysis with addition of inflammation
* group interaction terms (corresponding results in Section 3.3).
To assess the relationship between neuropsychological mea-
sures and biomarkers (WMH, CMB, CRP, and fibrinogen), linear
regressionmodels were independently fitted to neuropsychological
measures, and moderation by heritable risk factors was tested by
repeating the analysis with biomarker * group interaction terms
(corresponding results in Section 3.4). To examine whether the
trajectory of WMH, CMB, CRP, and fibrinogen related to changes in
reaction time, linear mixed effects models were fitted to neuro-
psychological measures; to test if these associations were moder-
ated by FH or APOE4, biomarker * group * interval interactions were
tested (corresponding results in Section 3.4).
All statistical analyses were conducted using R. Models were
estimated under a missing at randommissing data assumption using
maximum likelihood estimation. The lm function was used to fit
linear regression models, and glm was used for logistic regression
models. From the lme4 package (Bates et al., 2015), lmer was used to
fit linear mixed effects models, and glmer was used for mixed effects
logistic regression analysis. Statistical significancewas set at p< 0.05.
3. Results
Sample characteristics are presented in Table 1. The sample was
majority female (69%), had amean age of 52.2 years (SD 5.4), and an
average of 16.1 years of education (SD 3.4). Sex, age, and years of
education did not differ by FH or APOE4 carriership.
3.1. Group differences at baseline
Using general linear models, APOE4 carriership was related to
lower CRP levels and greater presence of CMB at baseline. On the
other hand, WMH and fibrinogen did not differ by FH or APOE4
carriership (Table 2, Figure A.1).
3.2. Longitudinal group differences
Significant FH * interval interaction in linear mixed effects
modeling showed greater WMH progression in FHþ than FH
Table 1
Participant characteristics
Measures Full sample158 Family history APOE4
FH FHþ p value (FH) APOE4 APOE4þ p value (APOE4)
n 158 73 85 98 60
Baseline demographics
Sex (N, % females)c 109, 69.0% 49, 67.1% 60, 70.6% 0.639 68, 69.4% 41, 68.3% 0.889
Age in yearse 52.2 (5.4) 51.1 (6.3) 53.1 (4.4) 0.113 52.7 (5.4) 51.3 (5.5) 0.083
Education in yearse 16.1 (3.4) 16.4 (3.8) 15.9 (3.0) 0.206 16.0 (3.5) 16.3 (3.1) 0.581
Family historyc 53.8% - 100% - 46.9% 65.0% 0.027f
APOE4c 38.0% 28.8% 45.9% 0.027f - 100% -
APOE2c 8.2% 8.2% 8.2% 0.997 9.2% 6.7% 0.576
Hypertensionc 16.5% 11.0% 21.2% 0.084 16.3% 16.7% 0.955
Baseline
WMH volumea,e 0.10 (0.15) 0.09 (0.13) 0.11 (0.17) 0.596 0.10 (0.17) 0.10 (0.13) 0.225
CMB (% present)c 21.5% 21.9% 21.2% 0.910 17.3% 28.3% 0.103
CRP (mg/L)e 2.7 (1.5) 2.7 (1.5) 2.8 (1.6) 0.586 2.9 (1.8) 2.4 (0.9) 0.030f
Fibrinogen 3.0 (0.7) 3.0 (0.7) 3.1 (0.7) 0.861 3.1 (0.7) 3.0 (0.6) 0.660
Reaction time (ms) b,d 341.1 (38.5) 334.9 (41.0) 346.5 (35.6) 0.063 338.7 (40.9) 345.0 (34.3) 0.304
Delayed recall 7.0 (1.5) 6.8 (1.6) 7.1 (1.4) 0.515 6.8 (1.6) 7.2 (1.5) 0.222
Stroop test 17.6 (3.1) 18.0 (3.0) 17.3 (3.2) 0.048f 17.7 (2.8) 17.4 (3.5) 0.549
Follow-up
WMH volumea,e 0.12 (0.19) 0.10 (0.14) 0.14 (0.23) 0.182 0.12 (0.22) 0.12 (0.14) 0.035f
CMB (% present)c 29.9% 30.6% 29.4% 0.876 26.5% 35.6% 0.230
CRP (mg/L)e 2.8 (1.8) 2.8 (1.8) 2.9 (1.8) 0.261 3.0 (2.0) 2.6 (1.4) 0.423
Fibrinogen 3.0 (0.7) 2.9 (0.7) 3.1 (0.7) 0.027f 3.1 (0.8) 3.0 (0.7) 0.605
Reaction time (ms) b,d 343.5 (38.9) 339.2 (39.8) 347.0 (38.0) 0.262 344.3 (42.7) 342.2 (32.2) 0.732
Delayed recall 7.3 (1.5) 7.4 (1.6) 7.1 (1.4) 0.143 7.3 (1.6) 7.2 (1.4) 0.454
Stroop test 17.8 (3.1) 17.9 (3.5) 17.7 (2.9) 0.291 17.9 (3.5) 17.5 (2.5) 0.075
a Values expressed as percentages (%), b,c Values as mean (standard deviation).
Key: CMB ¼ cerebral microbleeds, CRP ¼ C-reactive protein; FH ¼ parental family history of dementia, WMH ¼ white matter hyperintensities.
Missing data: CMB at follow-up (n ¼ 1), baseline CRP (n ¼ 1 missing; n ¼ 5 outliers excluded), follow-up CRP (n ¼ 3 missing; n ¼ 2 outliers excluded), fibrinogen (n ¼ 13),
follow-up fibrinogen (n ¼ 11), baseline reaction time (n ¼ 2), follow-up reaction time (n ¼ 5).
a Normalized volume adjusting for total intracranial volume ((WMH/TIV) * 100%).
b Longer reaction time indicates poorer performance.
c Chi-square test of independence.
d t-test.
e Mann-Whitney U test.
f p < 0.05.
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differences (FH, maternal FHþ, and paternal FHþ) further showed
that maternal FHþ (b ¼ 0.06, t ¼ 2.32, p ¼ 0.022), but not paternal
FHþ (b ¼ 0.05, t ¼ 1.43, p ¼ 0.155) related to greater WMH pro-
gression than FH. Similarly, interaction analysis of APOE4 * interval
showed that APOE4 carriers had greater WMH progression than
noncarriers (Table 2); this was observed for both periventricular
(b¼ 0.06, t¼ 2.19, p¼ 0.030) and deepWMH (b¼ 0.10, t¼ 3.65, p<
0.001). Adjusting for FH, APOE4 remained significantly associatedTable 2
Baseline and longitudinal group differences by family history and APOE4
Measures Standardized b Family history Standardized b APOE4
t value p value t value p value
Baseline
WMHa 0.02 0.12 0.907 0.11 0.69 0.489
CMBb 0.09 0.44 0.660 0.41 2.03 0.042d
CRPa 0.02 0.15 0.885 0.31 2.01 0.047d
Fibrinogena 0.08 0.48 0.632 0.00 0.03 0.980
Longitudinal change
WMHc 0.05 2.24 0.026d 0.08 3.48 <0.001e
CMBb 0.03 0.09 0.931 0.33 1.12 0.262
CRPc 0.01 0.10 0.924 0.06 0.74 0.458
Fibrinogenc 0.07 1.02 0.311 0.02 0.22 0.828
Note: All models adjusted for sex, age, and years of education.
a General linear model.
b Logistic regression model.
c Linear mixed effects model.
d p < 0.05.
e p < 0.001.with deep (b ¼ 0.10, t ¼ 3.47, p < 0.001), but not periventricular
WMH progression (b¼ 0.05, t¼ 1.92, p¼ 0.056). On the other hand,
changes in CMB, CRP, and fibrinogen did not differ by FH or APOE4
carriership (Table 2).
3.3. Association between SVD and inflammation
In logistic regression analysis, APOE4 * CRP interaction on CMB
was significant at follow-up, whereby the relationship between CRP
and CMB was more pronounced in APOE4 carriers than in non-
carriers (b ¼ 0.68, t ¼ 2.76, p ¼ 0.006); this applied to lobar CMB
(b ¼ 0.68, t ¼ 2.68, p ¼ 0.007), but not deep CMB (b < 0.01, t ¼ 0.01,
p ¼ 0.992). Separate regression models confirmed that the positive
associations between CRP and CMB were present in APOE4 carriers
but not noncarriers.
3.4. Reaction time
Interaction analysis in general linear models showed that FH
moderated the association between WMH and longer reaction
time, in that the relationship was more pronounced in FHþ rather
than FH (total WMH: b ¼ 0.52, t ¼ 3.11, p ¼ 0.002; periventricular
WMH: b ¼ 0.58, t ¼ 3.49, p < 0.001; deep WMH: b ¼ 0.37, t ¼ 2.25,
p ¼ 0.026). In terms of inflammation, significant interaction of CRP
and FH on reaction time showed that the relationship between
higher CRP levels and longer reaction time was stronger in FH
than FHþ (b ¼ 0.38, t ¼ 2.41, p ¼ 0.017).
Longitudinally, significant FH * WMH * interval interaction in
mixed effects analysis demonstrated that the association between
Fig. 3. Boxplots depict greater WMH progression in participants with parental history of dementia (FHþ) and APOE4 carriers (APOE4þ). WMH volumes are residuals controlling for
sex, age, and education. *p < 0.05, **p < 0.01, ***p < 0.001.
A. Low et al. / Neurobiology of Aging 98 (2021) 124e133 129WMH progression and increase in reaction time was stronger in
FHþ than FH (b ¼ 0.15, t ¼ 2.09, p ¼ 0.038) (Fig. 4). This effect was
observed in deep (b ¼ 0.19, t ¼ 2.77, p ¼ 0.006) but not periven-
tricular WMH (b ¼ 0.08, t ¼ 1.13, p ¼ 0.262). Independent models
fitted in the FHþ and FH groups separately confirmed that the
positive association was significant in FHþ but not the FH group.
Similarly, FH moderated the association between CMB progression
and longitudinal change in reaction time, in that the relationship
was stronger in FHþ than FH (b ¼ 0.15, t ¼ 2.12, p ¼ 0.036). These
interaction effects were not observed in relation to episodic
memory or executive function.
4. Discussion
We examined the effect of inherited predisposition to dementia
(parental history of dementia and/or the APOE4 allele) on SVD and
systemic inflammation in healthy midlife adults at baseline and
longitudinally. Inherited risk was associated with lower levels of
CRP, higher incidence of CMB, and greater increase in WMH overFig. 4. Plot of estimated marginal means of reaction time depicts a significant three-way int
time from linear mixed effects regression model. Note: Increasing reaction time equates to p
(moderate WMH progression). Linear mixed model adjusted for sex, age, and education.two years. Furthermore, the detrimental effect of SVD on reaction
time was more pronounced in those with FH relative to those
without, cross-sectionally and longitudinally. Conversely, the rela-
tionship between elevated CRP levels on reaction timewas stronger
in those without FH.
Increased WMH can be detected years before estimated symp-
tom onset in dominantly inherited AD, which suggests that WMH
may be an early event in AD pathogenesis (Lee et al., 2016). In this
study, although WMH severity did not differ by FH or APOE4 car-
riership at baseline, these risk factors were associated with greater
longitudinal progression of WMH over a two-year period. Adjusting
for FH, APOE4 was associated exclusively with deep (but not peri-
ventricular) WMH progression. This may be linked to etiological
differences between periventricular and deep WMH. Some studies
have found that only periventricular WMH is implicated in
increased risk of AD (Kim et al., 2015; Van Straaten et al., 2008),
whereas both periventricular and deep WMH are associated with
subcortical vascular dementia (Kim et al., 2015). Therefore, the
exclusive coupling of APOE4 and deep WMH could be taken toeraction of time (scan interval), family history, and total WMH progression on reaction
oorer performance. High and lowWMH progression was defined as þ/1 SD frommean
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ways. This is aligned with earlier studies showing that associations
between AD severity and WMH progression were diminished after
adjusting for APOE4 status, suggesting that WMH accumulation
may be driven by APOE4 rather than AD diagnosis (Sudre et al.,
2017). On the other hand, the heightened predisposition to de-
mentia associated with parental history extends beyond genetics,
and may also be driven by concomitant nongenetic factors such as
shared environment, lifestyle, and socioeconomic status (Scarabino
et al., 2016). In addition, we observed that greater WMH progres-
sion was observed in those with maternal but not paternal family
history of dementia, although unequal sample sizes warrant repli-
cation of this finding in a more balanced sample.
In our sample of healthymidlife adults, APOE4 carriers displayed
lower levels of CRP, a sensitive marker of systemic inflammation
(Pepys and Hirschfield, 2003). Given that SVD and CRP are known to
be positively associated (Lowet al., 2019), it is counterintuitive that a
risk factor (in this case, APOE4) would be associated positively with
one pathology but negatively with another. Although somewhat
surprising at first glance, these results are corroborated by earlier
studies similarly reporting lower levels of CRP in APOE4 carriers
(Chasman et al., 2006; Grönroos et al., 2008; Haan et al., 2008;
Hubacek et al., 2010; Mänttäri et al., 2001; März et al., 2004; Ukkola
et al., 2009). The juxtaposition of these contradictory findings
suggests that APOE4 and CRP could be operating along distinct
mechanistic pathways in relation to SVD, and may offer novel
insight into the causal pathways of APOE4 as a risk factor in neu-
rodegeneration. Despite being well documented in the literature,
the biological mechanisms responsible for the negative association
remain to be elucidated, although some attribute it to the down-
regulation of the mevalonate pathway in APOE4 carriers (März
et al., 2004). CRP and fibrinogen levels did not differ by family
historydthis is consistent with the only other study to our
knowledge examining CRP in relation to parental history of de-
mentia, which also reported nonsignificant findings (Van Exel et al.,
2009).
Inherited dementia risk had a dual effect on disease progression,
in that predisposed individuals not only experienced greater pro-
gression of SVD, but also more pronounced slowing of reaction time
in relation to SVD progression. In other words, the same degree of
pathologic progression was related to greater slowing of reaction
time in a person with inherited risk, than in a person without. This
suggests that at-risk individuals could have a heightened suscep-
tibility to vascular alterations. An alternative explanation is that
SVD progression linked to heritable risk factors may be accompa-
nied by other risk-related pathologies contributing to the cascade of
clinical deficits (Shi et al., 2017). In terms of inflammation, elevated
CRP levels were associated with slower reaction times, particularly
in those without parental history of dementia. The absence of this
association in thosewith family history suggests that poorer clinical
features in this group may be driven instead by incipient disease.
Notably, these findings were observed only in relation to reaction
time but not other neuropsychological measures, i.e., episodic
memory and executive function. This may be due to reaction time
being a particularly early clinical feature in SVD (Jouvent et al.,
2015; Richards et al., 2019), compared with the cognitive mea-
sures of memory and executive function which may be affected in
later disease stages.
Positive associations between SVD and CRP were present in in-
dividuals with inherited risk but not in those without. This is in line
with existing literature demonstrating the moderating effect of
APOE4 on the relationship between inflammation and SVD (Low
et al., 2019; Romero et al., 2012; Walker et al., 2017). Specifically,
APOE4 has been shown to moderate associations between CRP and
WMH (Walker et al., 2017) and between lipoprotein phospholipaseA2 and CMB (Romero et al., 2012). This may be attributed to the
increased propensity of APOE4 to promote inflammation and the
tendency for APOE4 carriers to produce stronger neuro-
inflammatory responses to peripheral systemic inflammation (Cash
et al., 2012; Lynch et al., 2003; Ophir et al., 2005). However, due to
the inability to ascribe directionality, alternative interpretations
should also be considered, whereby CRP acts as a moderator, i.e.,
APOE4 relates to greater SVD severity, but only in individuals with
high CRP levels. To that end, the finding that high CRP levels
amplified the detrimental effect of APOE4 on SVD suggests differ-
ential vulnerability, whereby individuals with heritable risk are
more susceptible to vascular risk factors and consequent paren-
chymal injury. This corresponds with existing evidence that APOE4
has a lower antioxidant capacity than other isoforms and is less
effective in protecting against oxidative stress, both of which could
exacerbate the deleterious effects of risk factors such as smoking
and low-grade inflammation (Dose et al., 2016; Jofre-Monseny
et al., 2008; Miyata and Smith, 1996). Although we are unable to
conclude the genetic overlap between SVD and AD in this present
study, past research suggests that AD shares some genetic overlap
specifically with SVD-related stroke but not other stroke subtypes
(Traylor et al., 2016). Nevertheless, the relationship between the
genetics of SVD and AD remains poorly understood at present and
warrants further investigation.
Biases in this study could have arisen from SVD ratings not being
blinded to time point. Baseline and follow-up WMH lesion maps
were compared side-by-side to improve consistency of WMH
delineation, while SWI scans from both time points were compared
with confirm that “new” CMB in follow-up scans were not present
at baseline. While intended to improve accuracy, the lack of
blinding to time point may have introduced implicit bias toward the
detection of greater SVD burden at follow-up. That being said, such
systemic biases would apply to the whole sample and should not
have affected the results on the group differences observed.
Furthermore, the degree of WMH and CMB progression observed
falls within the range of annual progression in previous reports
(Alber et al., 2019; Harper et al., 2018).
CMB incidence was higher than earlier reports in healthy pop-
ulations, likely due to (1) more sensitive detection of CMB afforded
by thin slice 3T SWI, which detects up to 3 times the number of CMB
compared with conventional 1.5 T GRE (Nandigam et al., 2009), and
(2) oversampling of participants with a family history of dementia
and, by extension, APOE4 carriership, a well established risk factor
for CMB in older adults (Poels et al., 2010). Majority of CMB positive
cases had a single microbleed, while only a handful had more than
one. Because of the dichotomization of CMB burden (present/ab-
sent), our ability to make inferences based on the degree of CMB
severity was limited.
A key strength of our study was its longitudinal design, which
enabled the investigation of pathologic progression across time.
Furthermore, we focused on a relatively young subclinical sample of
midlife adults, with and without heritable risk factors, which
allowed us to identify early biomarker changes in individuals at risk
of developing dementia. Several limitations warrant the replication
of results, including the relatively modest sample size, lack of
correction for multiple comparisons, missing values which may
introduce bias in the estimation of parameters, and FLAIR slice
thickness of 4 mm which may represent a limitation on WMH
quantification. In addition, inflammation was measured using pe-
ripheral blood markers, which may not be reflective of inflamma-
tion in the central nervous system. CRP levels are known to vary
widely over a short timescale, which could perhaps explain the
presence of associations between CRP and APOE4 at baseline but
not at follow-up. Furthermore, type of parental dementia was not
limited to AD but included mixed and vascular dementia, in which
A. Low et al. / Neurobiology of Aging 98 (2021) 124e133 131inherited risk may propagate primarily vascular but not AD pa-
thology, while diagnostic imprecision of parental dementia type is
another limitation. While FHþ participants were largely recruited
from dementia registries or through memory clinic referrals, FH
information of participants recruited from other sources relied on
self-report and was thus more susceptible to misreporting.
Furthermore, those recruited from other sources, including FH
participants, were observed to be less motivated and less likely to
return for follow-up assessments, resulting in greater dropout rates
within this subset. Finally, as the sample was predominantly white
(90%) (Ritchie et al., 2017), findings may not be applicable across
other ethnicities. Future studies with larger, multiethnic cohorts
and longer follow-up periods will be crucial to understand the
interaction between these pathologic processes across the adult
lifespan.
5. Conclusions
Our data demonstrate that cerebrovascular alterations can be
detected decades before dementia onset would occur in those at
risk. Individuals with parental history of dementia and/or APOE4
carriership experienced greater progression of cerebrovascular
disease, despite showing lower levels of inflammation. Progression
of cerebrovascular pathology also had more pronounced adverse
effects on reaction time in at-risk individuals. Taken together, our
findings suggest that inherited risk factors may accelerate the
progression of cerebrovascular damage as a function of heightened
vulnerability to vascular risk and low-grade inflammation, as
opposed to direct causative mechanisms. Clinically, our findings
signal the relevance of SVD and inflammation in relation to early
clinical features and disease trajectory.
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